Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Ubiquitin receptor PSMD4/Rpn10 is a novel therapeutic target in multiple myeloma

Ting Du, Yan Song, Arghya Ray, Xueping Wan, Yao Yao, Mehmet K. Samur, Chen Shen, Johany Penailillo, Tomasz Sewastianik, Yu-Tzu Tai, Mariateresa Fulciniti, Nikhil C. Munshi, Hao Wu, Ruben D. Carrasco, Dharminder Chauhan, Kenneth C. Anderson

Blood (2023) 141 (21): 2599–2614.

https://doi.org/10.1182/blood.2022017897

Published: 2023

Includes: Supplemental data

Journal Articles

Analysis of COVID-19-Associated Proteins Identifies TANK-Binding Kinase 1 As an Immunotherapeutic Target in Multiple Myeloma

Arghya Ray, Ting DU, Krishan Chauhan, Dharminder Chauhan, Kenneth C. Anderson

Blood (2022) 140 (Supplement 1): 7176–7177.

https://doi.org/10.1182/blood-2022-170226

Published: 2022

Journal Articles

26S Proteasome Non-Atpase Subunit 1, PSMD1/Rpn2, Is a Potential Therapeutic Target in Multiple Myeloma

Ting Du, Xueping Wan, Arghya Ray, Yao Yao, Ruben D. Carrasco, Mariateresa Fulciniti, Nikhil C Munshi, Dharminder Chauhan, Kenneth C. Anderson

Blood (2022) 140 (Supplement 1): 8853–8854.

https://doi.org/10.1182/blood-2022-163749

Published: 2022

Journal Articles

Biology and Prognostic Implications of Bone Marrow Plasmacytoid Dendritic Cells in Multiple Myeloma Pathogenesis By Single-Cell RNA Sequencing

Arghya Ray, Leutz Buon, Ting DU, Xueping Wan, Dharminder Chauhan, Kenneth C. Anderson

Blood (2022) 140 (Supplement 1): 12436–12437.

https://doi.org/10.1182/blood-2022-170593

Published: 2022

Journal Articles

CD73 Inhibition Reverses Immunosuppression and Has Potential As an Immunomodulatory Therapy in Patients with Multiple Myeloma

Melissa R Junttila, Arghya Ray, Robert Warne, Xi R Chen, Ting Du, Fang Lui, Subhash Katewa, Brian Blank, Jared Moore, Chudi Ndubaku, Christophe Colas, Pratik S Multani, Omar Nadeem, Dharminder Chauhan, Kenneth C. Anderson, Lori Friedman

Blood (2022) 140 (Supplement 1): 9957–9958.

https://doi.org/10.1182/blood-2022-168275

Published: 2022

Journal Articles

Combination of Melphalan Flufenamide and Anti-PD-L1 or Anti-CD38 Antibodies Enhances Anti-Myeloma Immunity

Arghya Ray, Ting DU, Nina N. Nupponen, Fredrik Lehmann, Jakob Lindberg, Joachim Gullbo, Paul G. Richardson, Dharminder Chauhan, Kenneth C. Anderson

Blood (2021) 138 (Supplement 1): 4357.

https://doi.org/10.1182/blood-2021-153705

Published: 2021

Journal Articles

CD73 Inhibition Overcomes Immunosuppression and Triggers Autologous T-Cell Mediated Multiple Myeloma Cell Lysis in the Bone Marrow Milieu

Arghya Ray, Melissa R Junttila, Ting DU, Dena Sutimantanapi, Xi Chen, Bob Warne, Jae Chang, Brian Blank, Kejia Wu, Jared Moore, Chudi Ndubaku, Tatiana Zavorotinskaya, Omar Nadeem, Lori Friedman, Dharminder Chauhan, Kenneth C. Anderson

Blood (2021) 138 (Supplement 1): 2675.

https://doi.org/10.1182/blood-2021-148174

Published: 2021

Journal Articles

Novel Cytokine-Mediated Mechanism of Action Identified By Quantitative Seroproteomics in Multiple Myeloma Patients Treated with Tagraxofusp, a Novel CD123-Directed Targeted Therapy

Arghya Ray, Clifton C. Mo, Ting DU, Arturo Olguin, Janice Chen, Christopher L Brooks, Tariq I. Mughal, Paul G. Richardson, Dharminder Chauhan, Kenneth C. Anderson

Blood (2021) 138 (Supplement 1): 1620.

https://doi.org/10.1182/blood-2021-153458

Published: 2021

Journal Articles

Ubiquitin Receptor PSMD4/Rpn10 Is a Novel Therapeutic Target in Myeloma

Ting DU, Yan Song, Arghya Ray, Ruben D. Carrasco, Sirano Dhe-Paganon, Dharminder Chauhan, Kenneth C. Anderson

Blood (2021) 138 (Supplement 1): 1591.

https://doi.org/10.1182/blood-2021-151377

Published: 2021

Journal Articles

A High Throughput Quantitative Seroproteomics Analysis of Multiple Myeloma Patients on Tagraxofusp Therapy Identifies Novel Cytokine-Assisted Mechanism of Action

Arghya Ray, PhD, Yan Song, PhD, Ting DU, PhD, Clifton C. Mo, MD, Arturo Olguin, Janice Chen, PhD, Christopher Brooks, PhD, Tariq I. Mughal, MD FRCP, Paul G. Richardson, MD, Dharminder Chauhan, PhD, Kenneth Anderson, MD

Blood (2020) 136 (Supplement 1): 34.

https://doi.org/10.1182/blood-2020-141571

Published: 2020

Journal Articles

Proteomic Characterization of Ubiquitin Receptor ADRM1/Rpn13

Yan Song, PhD, Ting DU, PhD, Arghya Ray, PhD, Krishan Chauhan, Mehmet K. Samur, PhD, Dharminder Chauhan, PhD, Kenneth Anderson, MD

Blood (2020) 136 (Supplement 1): 39.

https://doi.org/10.1182/blood-2020-139966

Published: 2020

Journal Articles

Blockade of Deubiquitylating Enzyme USP7 in Plasmacytoid Dendritic Cells Stimulates Anti-Myeloma Immunity

Arghya Ray, PhD, Ting DU, PhD, Yan Song, PhD, Sara J Buhrlage, PhD, Dharminder Chauhan, PhD, Kenneth Anderson, MD

Blood (2020) 136 (Supplement 1): 43.

https://doi.org/10.1182/blood-2020-138591

Published: 2020

Journal Articles

Analysis of Sars-Cov-2-Associated Proteins Identify Tank-Binding Kinase-1 As an Immunotherapeutic Target in Multiple Myeloma

Arghya Ray, PhD, Ting DU, PhD, Krishan Chauhan, Yan Song, PhD, Dharminder Chauhan, PhD, Kenneth Anderson, MD

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-143393

Published: 2020

Journal Articles

Proteomic Analysis Identifies Mechanism(s) of Overcoming Bortezomib-Resistance Via Targeting Ubiquitin Receptor Rpn13

Ting Du, PhD, Yan Song, PhD, Arghya Ray, PhD, Dharminder Chauhan, PhD, Kenneth C. Anderson, MD

Blood (2019) 134 (Supplement_1): 3074.

https://doi.org/10.1182/blood-2019-130236

Published: 2019

Journal Articles

Blockade of Ubiquitin Receptor Rpn13 in Plasmacytoid Dendritic Cells Enhances Anti-Myeloma Immunity

Arghya Ray, PhD, Yan Song, PhD, Ting DU, PhD, Dharminder Chauhan, PhD, Kenneth C. Anderson, MD

Blood (2019) 134 (Supplement_1): 3098.

https://doi.org/10.1182/blood-2019-122901

Published: 2019

Journal Articles

Preclinical Validation of Ubiquitin Receptor PSMD4 As Therapeutic Target in Multiple Myeloma

Yan Song, PhD, Ting DU, PhD, Arghya Ray, PhD, Dharminder Chauhan, PhD, Kenneth C. Anderson, MD

Blood (2019) 134 (Supplement_1): 4403.

https://doi.org/10.1182/blood-2019-122952

Published: 2019

Journal Articles

miR-142-3p acts as an essential modulator of neutrophil development in zebrafish

Hong-Bo Fan, Yi-Jie Liu, Lei Wang, Ting-Ting Du, Mei Dong, Li Gao, Zhao-Zheng Meng, Yi Jin, Yi Chen, Min Deng, Huang-Tian Yang, Qing Jing, Ai-Hua Gu, Ting-Xi Liu, Yong Zhou

Blood (2014) 124 (8): 1320–1330.

https://doi.org/10.1182/blood-2013-12-545012

Published: 2014

Includes: Supplemental data

Journal Articles

Mir-144 selectively regulates embryonic α-hemoglobin synthesis during primitive erythropoiesis

Yan-Fang Fu, Ting-Ting Du, Mei Dong, Kang-Yong Zhu, Chang-Bin Jing, Yong Zhang, Lei Wang, Hong-Bo Fan, Yi Chen, Yi Jin, Gui-Ping Yue, Sai-Juan Chen, Zhu Chen, Qiu-Hua Huang, Qing Jing, Min Deng, Ting Xi Liu

Blood (2009) 113 (6): 1340–1349.

https://doi.org/10.1182/blood-2008-08-174854

Published: 2009

Includes: Supplemental data

NARROW

Ubiquitin receptor PSMD4/Rpn10 is a novel therapeutic target in multiple myeloma

Analysis of COVID-19-Associated Proteins Identifies TANK-Binding Kinase 1 As an Immunotherapeutic Target in Multiple Myeloma

26S Proteasome Non-Atpase Subunit 1, PSMD1/Rpn2, Is a Potential Therapeutic Target in Multiple Myeloma

Biology and Prognostic Implications of Bone Marrow Plasmacytoid Dendritic Cells in Multiple Myeloma Pathogenesis By Single-Cell RNA Sequencing

CD73 Inhibition Reverses Immunosuppression and Has Potential As an Immunomodulatory Therapy in Patients with Multiple Myeloma

Combination of Melphalan Flufenamide and Anti-PD-L1 or Anti-CD38 Antibodies Enhances Anti-Myeloma Immunity

CD73 Inhibition Overcomes Immunosuppression and Triggers Autologous T-Cell Mediated Multiple Myeloma Cell Lysis in the Bone Marrow Milieu

Novel Cytokine-Mediated Mechanism of Action Identified By Quantitative Seroproteomics in Multiple Myeloma Patients Treated with Tagraxofusp, a Novel CD123-Directed Targeted Therapy

Ubiquitin Receptor PSMD4/Rpn10 Is a Novel Therapeutic Target in Myeloma

A High Throughput Quantitative Seroproteomics Analysis of Multiple Myeloma Patients on Tagraxofusp Therapy Identifies Novel Cytokine-Assisted Mechanism of Action

Proteomic Characterization of Ubiquitin Receptor ADRM1/Rpn13

Blockade of Deubiquitylating Enzyme USP7 in Plasmacytoid Dendritic Cells Stimulates Anti-Myeloma Immunity

Analysis of Sars-Cov-2-Associated Proteins Identify Tank-Binding Kinase-1 As an Immunotherapeutic Target in Multiple Myeloma

Proteomic Analysis Identifies Mechanism(s) of Overcoming Bortezomib-Resistance Via Targeting Ubiquitin Receptor Rpn13

Blockade of Ubiquitin Receptor Rpn13 in Plasmacytoid Dendritic Cells Enhances Anti-Myeloma Immunity

Preclinical Validation of Ubiquitin Receptor PSMD4 As Therapeutic Target in Multiple Myeloma

miR-142-3p acts as an essential modulator of neutrophil development in zebrafish

Mir-144 selectively regulates embryonic α-hemoglobin synthesis during primitive erythropoiesis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only